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New technologies have allowed remote real-time electronic recording of symptoms and
spirometry. The feasibility of utilising this technology in COPD patients has not been investi-
gated.
This is a feasibility study. The primary objective is to determine whether the use of an elec-
tronic diary with a portable spirometer can be performed by COPD patients with a moderate to
severe disease. Secondary objectives are to investigate the value of this method in early
detection of acute exacerbations of COPD (AECOPD).
In this 6-month study, 18 patients recorded daily their symptom score and spirometry. Data
was sent on real time. AECOPD which was defined according to pre-set criteria were noted.
Spirometry values and scores for health-related quality of life were compared between the
start and the end of the study. Hospitalisation rate due to AECOPD was compared with
a parallel period in the previous year.
On average, patients were able to record 77% of their total study days. The system detected
73% of AECOPD. In further 27% of AECOPD patients sought treatment although the change in
symptoms did not meet AECOPD definition. The number of COPD-related hospitalisations
significantly reduced compared to the previous year. There was a significant increase in
FEV1 and FVC from the start to the end of the study.
The remote monitoring device used in this study can be used in COPD patients. AECOPD was
detected early in the majority of cases. Hospitalisation rate due to AECOPD was reduced and
FEV1 and FVC values increased during the study.
ª 2009 Elsevier Ltd. All rights reserved.4 01179282620; fax: þ44
stol.nhs.uk (N.A. Jarad).
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Monitoring health status in COPD patients with the view of
early detection of acute exacerbation of Chronic Obstruc-
tive Pulmonary Disease (AECOPD) is one of the goals of the
respiratory community. AECOPD is an important feature of.
Remote daily real-time monitoring in patients 1321the disease. Frequent pulmonary exacerbations have been
shown to cause deterioration in health status,1e3 quality of
life4 and FEV1.
5
The exact definition of AECOPD remains contentious
although is often characterised by an increase in symptoms
including cough, sputum volume/purulence and shortness
of breath sufficient enough to make patients seeking help
and the physicians escalating treatment.1,6e11
Failure to treat repeated AECOPD may lead to gradual
decline in lung function whereas early management of
AECOPD is thought to be associated with shorter duration of
symptoms12 and to enhance recovery of AECOPD.13 For the
management of AECOPD to happen early, patients have to
present to their clinicians with increase in symptoms. Many
studies, however, continue to show that many AECOPD are
unreported.5,14
Educational intervention with supervision for chronic
Obstructive Pulmonary Disease (COPD) patients has been
shown to reduce both short- and long-term hospitalisation
suggesting that an educational approach may be beneficial
to patients managing their disease.15 Additionally, guided
self-care by recording daily peak expiratory flow and
symptoms in a paper diary has been demonstrated to
reduce hospitalisations due to AECOPD.16 The use of paper
diaries is suboptimal as the diagnosis of exacerbations often
occurs in retrospect upon inspection of the diary.
It has been suggested that the use of an electronic diary
may be a mechanism to rectifying the lack of early AECOPD
reporting.17 Electronic diaries using modern communication
devices enable daily recording of symptoms and spirometry
to be sent to the treating clinicians on a real-time basis,
thus allowing early intervention as needed.
We have previously described the value of electronic
daily monitoring in cystic fibrosis (CF) and its use in
understanding symptom fluctuation and early detection of
acute exacerbations of CF (published in abstract form. Full
manuscript is under consideration for publication at
present).18 Because of the young age of CF patients, it is
possible that they are able to use modern electronic
methods of communication more readily than COPD
patients, particularly the more elderly patients and those
with advanced disease.
The current feasibility study is primarily designed to
determine whether an electronic real-time remote moni-
toring system can be used by COPD patients with
a moderate to severe disease for adequate number of days
to allow monitoring of their health status and early
detection of signs of AECOPD.
Patients, material and methods
Patients
This is a single centre study. All patients were recruited
from the Department of Respiratory Medicine, Bristol Royal
Infirmary. Southmead Research Ethics Committee, Bristol
approved the study.
The inclusion criteria were: diagnosis of COPD, 40
years, an FEV1< 80% predicted, FEV1/FVC< 70, 10 pack-
year smoking history and free from AECOPD for 2 weeks
prior to entering the study. Diagnosis of COPD was based ondocumented diagnosis of the diseases. Patients in whom
asthma diagnosis was recorded in medical notes were
excluded from the study. Patients with other reasons for
obstructive defect (for example bronchiectasis) were
excluded from the study.
Patients who had any co-morbidity serious enough to
shorten life to less than one year in the estimate of the
investigator or had undergone lung surgery were not
included. Patients residing in an area with no network
connectivity and/or a significant cognitive problem were
also excluded. All patients were given sufficient time to
read the patient information sheet and any questions were
answered in advance. Patients’ General Practitioners (GPs)
were informed of the study at the point of enrolment.
Study design
This was a 6-month feasibility study. At the start of the
study basic demographic data, a medical history, current
medications and reproducible lung function (FEV1, FVC)
were recorded using a Spiro USB Spirometer (Micro Medical,
UK). An AR20 quality of life questionnaire was also
completed.21 At the end of the study lung function was
recorded and the AR20 questionnaire was repeated. Change
in FEV1 and FVC as assessed by this method, rather by
patients own daily recording, was taken for analysis
between the start and the end of the study.
The device
An XDa system is a mobile-enabled Personal Digital Assis-
tant. The XDa systems used in this study were provided by
O2 Telecommunication, UK and were attachable to a hand
held Vitalograph (Vitalograph, Buckinghamshire e UK) with
a cable designed by e-san limited, Oxford (Fig. 1A). Soft-
ware written by e-san limited was installed on the XDa
system which allowed patients to easily access and enter
data on their symptoms as well as to records their lung
function. E-san limited was taken over by tþ Medical during
the study.
Each patient had a unique identifying number linked to
their Subscriber Identity Module (SIM) card. When the
device was handed to another patient at the end of their
enrolment, the number was changed to identify the new
patient.
All patients were trained upon enrolment in the study.
The device was provided after patients demonstrated
mastery of recording symptoms and spirometry. In addition,
all patients were provided with an information sheet illus-
trating how to use the device and a hand held spirometer
and 2 nose clips. Upon enrolment into the study,
researchers were available to answer questions and
a technical helpline with e-san limited or tþ Medical was
available.
Daily recording of symptoms and lung function
Patients were asked to record their symptoms and spirom-
etry once daily in the evening. Upon switching on the XDa
system there was clear entry into the programme. All
symptom-related questions were pre-set (Table 1, Fig. 1B).
Figure 1 A) XDa mobile-enabled Personal Digital Assistant with a spirometer attached. B) Series of questions on the XDa system
that patients responded to on a daily basis and instruction for performing spirometry. C) Transmission of the results in real time to
the research team (Please also see Table 1).
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using a stylet provided with the device. Grading of symp-
toms was adapted from the MRC questionnaire on respira-
tory symptoms.19Each symptom was graded from 1 (mild) to 5 (severe).
Patients were asked to choose the severity grade which best
described their symptoms for that day. In addition they were
asked if they visited amedical professional that day (Yes/No)
Table 1 Symptoms questionnaire. Each symptom is scored from 1 to 5 (please see text).
Breathlessness Fatigue Sputum volume Sputum colour
None None None None
Breathless after vigorous activities
(e.g. gardening or cleaning)
Somewhat tired Teaspoon White/grey
Breathless after light activities
(e.g. washing)
So tired that you need to
rest regularly
Less than ½ egg cup Yellow
Breathless after washing and dressing Prevented from your daily
home routine (e.g. shopping or working)
Between ½-1 egg cup Greenish
Breathless at rest or at minimal effort Unable to get out of bed More than an egg cup Brownish
Remote daily real-time monitoring in patients 1323and if they had a medication change that day (Yes/No). The
device then prompted patients to attach the spirometer.
Spirometry was performed according to the recommen-
dations of the British Thoracic Society/Association of
Respiratory Technicians and Physiologists (BTS/ARTP)
guidelines.20 Patients were asked to perform 3 spirometry
attempts. If the readings differed by 10%, the reproduc-
ibility criteria were met. If reproducibility was not met the
patients were asked to perform additional manoeuvres.
After a maximum of 5 attempts the spirometer switched
itself off. The individual highest and reproducible FEV1
and FVC were selected for each patient per day. After
recording FEV1 patients were asked to click ‘send’ (Fig. 1B)
and the data was sent to the research centre in real
time (Fig. 1C).
Reading and managing symptoms
A website was created for the study as a collaborative
effort between one of the researchers (NAJ) of the
Department of Respiratory Medicine, Bristol and e-san
limited. Only, password-permitted physicians and research
scientists could access to the website. A time-score plot
was designed for each patient. Each symptom score and the
best FEV1 value were plotted on a daily basis (Fig. 2).
To establish a baseline all patients entered an exacer-
bation-free run-in period of 14 days where they recorded
symptom score and lung function as described above.
Baseline for each symptom score and FEV1 was the median
and the mean value respectively of the 14-day run-in period
recordings. If an AECOPD occurred during this period, the
run-in period was re-started 14 days from the end of the
AECOPD. Patients who had 2 AECOPD during the run-in
period were excluded from the study. Once the run-in
period was successfully completed the baseline automati-
cally appeared on the patients time-score plot and the
patient entered the study.
During the study phase patients recorded symptom
score, answered the medication related questions and
recorded their spirometry as previously described.
AECOPD was defined using the principles of the BTS/NICE
guidelines22 as ‘‘A sustained worsening of symptom score
from baseline that is acute in onset’’. Commonly reported
symptoms are worsening of breathlessness, cough,
increased sputum production and change in sputum colour.
We also arbitrary considered a 10% decline in FEV1 from
baseline for 2 or more consecutive days to represent anAECOPD. AECOPD was, therefore, regarded to be present if
at least one of the following criteria was encountered:
1. An increase of at least 1 degree of 2 symptom scores
and/or a decline in FEV1 10% from baseline for 2
successive days.
2. A patient presenting with symptoms they felt to be
those of AECOPD and sought help that resulted in them
being given a course of antibiotics and/or prednisolone.
When the recordings met criteria number 1 a red line
appeared on the corresponding day of the patient’s time-
score plot (Fig. 2) and an electronic mail message was
automatically sent to the research team.
Once an AECOPD was detected a researcher telephoned
the patient and offered treatment. Whether or not the
treatment started was a consensus between the doctor and
the patient. An AECOPD detected by the device was coun-
ted irrespective of whether or not the patient accepted
escalation of treatment. Management of AECOPD differed
according to the phenotype of the AECOPD. If the AECOPD
was manifested with increased breathlessness, fatigue or
by a decline in lung function tests, patients were advised to
take prednisolone only. If these symptoms were associated
with an increase in sputum volume or purulence or if the
AECOPD was manifested by these 2 symptoms alone they
were advised to take antibiotics as well.
The end of exacerbation was considered to have
occurred when the symptom score reduced so that they no
longer met the definition of AECOPD. The exacerbation red
line automatically disappeared at the end of exacerbation.
All patients were provided with a 7-day oral course of
antibiotics and a 14-day oral course of prednisolone.
According to hospital microbiology data, amoxicillineclav-
ulanic acid combination (co-amoxyclav) 625 mg three times
daily was the most clinically suitable antibiotic. Cipro-
floxacin 500 mg twice daily was provided for penicillin-
allergic patients. Prednisolone was prescribed at 30 mg
once daily. The patients’ GPs were advised to replenish the
medication if used. If there was difficulty obtaining medi-
cations from GPs, the research team replenished the
patient’s supply.
Upon changing medications, patients recorded this on
their device. In addition they completed a form provided
and sent it to the research team in a pre-paid envelope
notifying the team of who they visited and/or the medi-
cation change. This allowed the additional advantage of the
Figure 2 Time-score plots of results transmitted from patient electronic diaries to the research team. The horizontal red lines
indicate median baseline values for each symptom score or the mean baseline value for FEV1. The horizontal blue line on the FEV1
charts indicates a 10% decline in FEV1 from the baseline value. Detection of an AECOPD is indicated by the red highlighted area
which spontaneously appears on the charts at the point of detection and automatically disappears at the end of exacerbation.
A) Time-score plot of an AECOPD detected by a 10% decline in FEV1 over 2 successive days. B) Time-score plot of an AECOPD
detected by an increase in 2 symptoms over 2 successive days. Antibiotics and prednisolone were promptly started, symptoms
lasted for 6 days and sputum colour and fatigue were the last symptoms to normalise.
1324 Z.M. Sund et al.research team to track the date of the AECOPD that the
system did not detect.
Outcome measures
The primary objective of the study was to quantify the
number of days out of the total 180 days study period in
which patients were able to record their symptoms. Other
objectives included 1. the number of AECOPD detected and
undetected by the monitoring system, 2. change in FEV1,
FVC, AR20 score from the start to the end of the study and
3. the number of hospital admissions and length of stay forAECOPD during the study period as compared to those
during a parallel 6 months in the previous year as detected
from hospital records. It was not possible to compare the
number of AECOPD with the same period of time in the
previous year as many AECOPD were treated outside
hospital and reliable data was not available.
Statistical analysis
Statistical analysis was aided by the Research and Devel-
opment Support Unit at the Bristol Royal Infirmary. Data
was analysed using SPSS statistics (version 14).
Table 2 Patients’ demographic data at baseline.
Patients who used
the device for 6 months
nZ 18
Mean age (SD) years 65 (9.50)
Gender (female/male) 6:13
Mean FEV1 (SD) litres 1.04 (0.37)
Mean FEV1 (SD) % predicted 36.37 (13.35)
Mean FVC (SD) litres 2.62 (0.64)
Mean FVC (SD) % predicted 71.95 (17.26)
On long acting beta2 agonists 18/18 (100%)
On inhaled corticosteroids 14/18 (77.8%)
On long acting anticholinergic agents 9/18 (50%)
FEV1: forced expiratory volume in the first second of expiration;
and FVC: forced vital capacity.
Table 3 Characteristics of the acute exacerbations of
chronic obstructive pulmonary disease detected during the
study period. Patients concurred, when patients agreed
that the increase in symptoms was sufficient enough to
require treatment escalation. Vice a versa for patients who
did not concur.
Exacerbation
lepisodes,
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spent in hospital due to AECOPD between the study year
and the same period of time in the parallel previous year
were analysed using Wilcoxon’s Signed Ranks Test. AR20
quality of life score between the start and the end of the
study was analysed in the same way. A paired t-test was
also used to compare spirometric values (FEV1 and FVC)
from the start to the end of the study period. Statistical
significance was set at the 5% level.
Using the rate of hospitalisation data, a sample size
calculation was used to estimate the number of patients
needed for a future adequately powered randomised
controlled trial comparing daily monitoring with normal
care.
Results
From October 2005 to August 2006, 22 consenting patients
were screened, 19 were included in the study. In one
patient the data could not be analysed due to a fault in the
device leaving 18 patients in the study (Fig. 3). Their
baseline characteristics can be seen in Table 2.
During the study, recordings were made on average in
77% of study days (range 70e92%). A total of 75 AECOPD
were diagnosed out of which 55 (73%) were detected by the
remote monitoring system. In 41/55 (75%) AECOPD detec-
ted by the device, the patient agreed that their increase in
symptoms was sufficient for escalation of treatment. In 14/
55 (25%) AECOPD detected, patients did not feel that the
increase in symptoms was sufficient enough for them to
seek help. Five patients had 2 or less AECOPD throughout
study period. The rest had more than 2 AECOPD.
Table 3 shows details of AECOPD throughout the study
period.
Conversely, in 20/75 (27%) AECOPD patients presented
with symptoms who needed treatment with antibiotics
and/or corticosteroids when their symptom scores on their
recordings were not sufficient to meet our pre-setPatients screened
n= 22
Patients taught how to
use the device, n=20
Completed 6 months
n=18
Asthmatics
n=2
Unable to use the device n=1
Technical difficulty n=1
Figure 3 Study patients.definition for AECOPD. Throughout the study a total of 57
courses of antibiotics and a total of 50 courses of prednis-
olone were taken. Table 3 shows characteristics of the
AECOPD.
Out of the 75 exacerbations, 6 exacerbations were
detected by decline in FEV1 alone. In 4 patients concurred
with the diagnosis and were treated by oral corticosteroids.
FEV1 returned to baseline value at the end of the treatment
in all treated patients.
Data on hospitalisations due to AECOPD was obtained
from reviewing patient medical notes for all patients.total numberZ 75
Exacerbations not detected
by the device
20/75 (27%)
Exacerbations detected
by the device
55/75 (73%)
Exacerbations detected by the device
Exacerbations detected
by the device e patients concurred
41/55 (75%)
Exacerbations detected
by the device e patients
did not concur
14/55 (25%)
Exacerbations diagnosed
by >10% decline
in FEV1 only
6/55 (11%)
Exacerbations manifested
with increase in symptom
score only
37/55 (67%)
Exacerbations manifested
with increase in symptom
score and >10% decline
in FEV1
12/55 (22%)
FEV1: forced expiratory volume in the first second of expiration.
p= 0.038
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1326 Z.M. Sund et al.During the study period there were 6 hospitalisations (0.33
per patient) due to AECOPD, compared to 14 (0.78 per
patient) in the same 6 months in the previous year,
pZ 0.027 (Fig. 4).
The median length of stay for AECOPD in the study
period was 0 day (25% percentile 0 days, 75% percentile 4.5
days), compared to 4 days (25% percentile 0 days, 75%
percentile 6.5 days) for the parallel period in the year prior
to the study. This comparison did not reach statistical
significance, pZ 0.23 (Fig. 4).
Over the 6-month study, there was a 66-ml increase in
mean FEV1 from 1.04 (SD 0.37) litres to 1.107 (SD 0.37) litres
pZ 0.038. Similarity there was a 300-ml increase in FVC
from 2.62 (SD 0.64) to 2.92 (SD 0.80) litres pZ 0.050
(Fig. 5).p= 0.027
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Figure 4 Hospitalisation rate (A) and length of stay in
hospital (B) during the study period compared to the parallel
period of time for each patient in the previous year.
p= 0.050
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Figure 5 Change in FEV1 and FVC from the start to the end of
the study period. FEV1: forced expiratory volume in the first
second of expiration; and FVC: forced vital capacity.In contrast there was no change in the AR20 health-
related quality of life score with a median score of 11 at the
beginning and at the end of the study, pZ 0.946.
Using the rate of hospitalisation as an outcome measure,
a future adequately powered randomised controlled trial
comparing the intervention using this method with the
usual care would require a sample size of 94 patients in
each study arm (total 188 patients) to achieve 80% power to
detect a difference in means if these findings were to be
replicated using a two-group t-test with a 5% 2-sided
significance level.
Discussion
This feasibility study shows that COPD patients can use
modern electronic device to monitor their symptoms and
spirometry in over three quarter of study days. The device
was able to detect the majority of AECOPD. For patients
Remote daily real-time monitoring in patients 1327included in the study, there has been a modest improve-
ment in spirometry values at the end of the study and
a reduction in hospitalisation rate but not length of stay
due to AECOPD. Daily recording has not adversely affect
health status. The study has several limitations e there is
no control group, the number of patients is small and the
duration of study is short.
AECOPD has been defined differently in different studies.
An increase in two major symptoms over two consecutive
days was a defining event in one study.23 This is similar to the
definition used for symptom increase in our study. In another
large trial24 an increase in more than one symptom for three
consecutive days was used to define AECOPD. Unlike
previous studies where peak flow rate was used for daily
monitoring,11,12,23 FEV1 was recorded in this study.
The decline in FEV1 of 10% or more over two consecutive
days was used to define exacerbation even when symptoms
did not change. We recognize that it may not be an
acceptable criterion for AECOPD by all clinicians and this
could potentially be regarded as a limitation to this study.
But this study has helped to show that AECOPD by decline of
FEV1 alone occurred only in the minority of exacerbations.
We accept that defining exacerbations in future similar
studies may need to be unified, but the primary objective
of this study is to assess the competency and consistency of
COPD patients in recording symptoms and spirometry for 6
months period.
It has previously been recommended that COPD patients
need to have an increased awareness of their symptoms and
should promptly start on treatment for AECOPD.1,11,12 This
would reduce the health burden in COPD and could
decrease the severity of AECOPD by reducing declines in
lung function thereby increasing recovery rate. In our
study, treatment of AECOPD was communicated to the
patients upon detection and most episodes were treated.
We have ‘phenotyped’ AECOPD into 2 groups and
designed the treatment according to symptoms. All patients
took prednisolone for AECOPD but only those with increased
muco-purulent sputum took antibiotics. Phenotyping
AECOPD has shown to be important in a recent study which
compared the effect of long acting anti-cholinergic agent
(tiotropium) with a combination of inhaled corticosteroid
(fluticasone) and long acting beta2 agonists (salmeterol).14 It
was apparent that although the rate of prevention of total
reported and unreported AECOPDwas similar in the two arms
of treatment, exacerbations that were treated with oral
prednisolone were prevented more effectively with
a combination of salmeterol and fluticasone. On the other
hand, exacerbations that required antibiotics were pre-
vented more effectively with tiotropium.
As stated previously, most AECOPD in this study man-
ifested with increased symptoms without a significant
change in spirometry. Decline in FEV1 alone was seldom
encountered as the reason for AECOPD detection. A
previous report suggested that changes in FEV1 during
exacerbations may be small and was not reliable for
detecting AECOPD.1 Another possibility is the fact that the
decrease in FEV1 lagged behind an increase in symptoms
and that the prompt treatment for may have obviated the
decline in FEV1.
In our study, over one quarter of patients sought treat-
ment for AECOPD despite the fact that changes in theirsymptoms and lung function tests did not meet the pre-set
definition of AECOPD. The number of patients in this study
is not large enough to characterise patients who had low
threshold of starting the treatment. A possible reason is
that the change of scoring system that we adapted from the
MRC respiratory questionnaire may not have been sensitive
enough to detect AECOPD. Some patients may have sought
help based on previous experience of symptom deteriora-
tion prior to change in symptoms meeting the pre-set
definition of AECOPD. Another possibility is that upper
respiratory tract symptoms such as nasal discharge and
congestion, and sore throat which this system did not
measure might have prompted GP visits. These symptoms
were reported in other studies in a significant number of
patients over the prodromal phase (7 days before onset of
exacerbation) prior to AECOPD.11,23
Hospitalisation for AECOPD is not only a major health-
care cost1,25 but has been associated with a major decline
in health status,1e3 quality of life4 and FEV1.
5 This study
shows that this intervention significantly reduced the
number of hospitalisations during the study period. Despite
the obvious shortcomings of comparing the rate of hospi-
talisations with historic data, we did the analysis as we
have a reliable data on hospital admissions. Similar results
were not seen in a recently published study in which
a nurse-led package did not reduce hospitalisation,
although was associated with reduced mortality.26 In our
study, it is not possible to identify whether being part of
this research or whether the early detection and treatment
of AECOPD might account of this apparent reduction in
hospitalisation.
This study shows that remote daily monitoring of symp-
toms in COPD over a 6-month period leads to a small
increase in both FEV1 and FVC. This may reflect a ‘peaking’
of the efficacy of intervention at the 2e6-month point
which has been reported in larger trials.27,28 Although this
might be the case, we acknowledge that our study, unlike
these trials, did not compare an intervention with no
intervention or placebo. It has to be considered that the
improvement in spirometry may reflect a true efficacy of
early intervention with early treatment for most AECOPD.
As in the hospitalisation rate, it is not possible at this stage
to determine the cause of this improvement be it the daily
monitoring, education, early therapy or simply being part
of this study has the greatest effect on outcome.
An XDa system has been used in this study, but other
modalities for communications equipment with the appro-
priate software could be used. This includes an ordinary
mobile phone, an internet connection or a remote control
television. In practical terms, this method could be used in
selected patients and for a short or long period of time.
Patients with impaired mobility, those who live in remote
areas or those who are anxious of attending healthcare
premises might find this technique helpful. This technique
once established could be adapted to other diseases such as
asthma, and congestive cardiac failure although care must
to be taken to prevent over treatment as a result of lower
threshold of intervention.
Based on the hospitalisation rate, we have calculated
that, compared to usual care, a larger randomised control
trial of 188 patients is required to explore the value remote
monitoring of AECOPD. If this intervention to be compared
1328 Z.M. Sund et al.with other interventions such as regular telephone consul-
tations or paper diaries, a larger number of patients are
needed to detect difference in hospitalisation rate. In any
case, we suggest that, an adequately powered trial, is
needed since interventions aimed at delaying the progres-
sion of COPD and improve access to healthcare are
considered high priority areas.
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